New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
Ascendis Pharma(ASND) Newsfilter·2024-01-29 21:30Eyconis成立 - Ascendis Pharma与Frazier Life Sciences共同成立了Eyconis, Inc.，旨在全球开发、生产和商业化TransCon眼科资产[1] - Eyconis由眼科行业资深人士Emmett Cunningham, M.D., Ph.D., MPH和生物制药高管Oliver Boris Stauch领导[2] - Eyconis计划利用TransCon技术平台开发创新的、最佳的视网膜疾病疗法[3]